ライフサイエンスコーパス: leiomyoma

1 impact of reader experience (29 sarcomas; 30 leiomyomas).

2 nsurgical therapeutic strategies for uterine leiomyoma.

3 ently in leiomyosarcomas and not detected in leiomyoma.

4 ed in malignant myeloid diseases and uterine leiomyoma.

5 olymorphism was also found in one intramural leiomyoma.

6 cells causing smooth muscle tumors (SMTs) or leiomyoma.

7 f minimally invasive surgery for symptomatic leiomyoma.

8 elvis of a physician treated for symptomatic leiomyoma.

9 may be used to facilitate extraction of the leiomyoma.

10 lipoleiomyoma is a rare and specific type of leiomyoma.

11 dupAAA mutation in the FH gene had cutaneous leiomyoma.

12 tional dysregulation in MED12 mutant uterine leiomyomas.

13 raining set consisted of 51 sarcomas and 105 leiomyomas.

14 ration of novel target therapies for uterine leiomyomas.

15 n with cutaneous leiomyomas also had uterine leiomyomas.

16 utations in FH in 35 families with cutaneous leiomyomas.

17 ividuals (47 women and 34 men) had cutaneous leiomyomas.

18 al myometria, was expressed in 16 of 19 Eker leiomyomas.

19 leiomyoma volume and location, and number of leiomyomas.

20 ndrome called multiple cutaneous and uterine leiomyomas.

21 d family with multiple cutaneous and uterine leiomyomas.

22 easured in 20 patients who underwent UAE for leiomyomas.

23 uent in leiomyosarcomas and absent in benign leiomyomas.

24 MR) evaluation of known or suspected uterine leiomyomas.

25 for chromosome 10 was not found in 13 benign leiomyomas.

26 ressure, sensation of mass), or both, due to leiomyomas.

27 esting a pathogenesis in common with uterine leiomyomas.

28 and HMGA2-overexpressing (HMGA2-LM) uterine leiomyomas.

29 serve this purpose in symptomatic women with leiomyomas.

30 s, liver cysts, thyroid nodules, and uterine leiomyomas.

31 sting a role for this gene in the genesis of leiomyomas.

32 ignant uterine sarcomas from benign atypical leiomyomas.

33 ility, which is frequently observed in human leiomyomas.

34 HIFU is used clinically in the treatment of leiomyomas.

35 riptional and epigenetic changes observed in leiomyomas.

36 ssion of versican in human LMS versus benign leiomyomas.

37 ogesterone, leading to the growth of uterine leiomyomas.

38 ling chromothripsis were a common feature of leiomyomas.

39 ely common hormone-responsive tumor, uterine leiomyoma, a tumor with a significant impact on women's

40 Formation of new leiomyomas after these conservative therapies remains a

41 ight percent (46/47) of women with cutaneous leiomyomas also had uterine leiomyomas.

42 INGS: LMSP comprised approximately 1% of all leiomyoma and 2% of all myometrium-derived cells.

43 se histological features resembling those of leiomyoma and leiomyosarcoma.

44 e effects of endogenous estrogens on uterine leiomyoma and may contribute to a complex hormonal milie

45 heparin were equally effective at inhibiting leiomyoma and myometrial smooth muscle cell proliferatio

46 HMGA1 was expressed in both leiomyoma and normal myometria.

47 ng activity in protein extracts from uterine leiomyoma and normal myometrium tissues.

48 in the development of cutaneous and uterine leiomyoma and renal cell cancer in this syndrome.

49 The treatment of primary leiomyoma and smooth muscle cells (n = 29) with various

50 y, we conducted transcriptional profiling of leiomyoma and unaffected myometrium from humans and Eker

51 osomal dominant pattern, manifesting as skin leiomyoma and uterine fibroids in affected individuals.

52 No mutant bands were found in 3 leiomyomas and 11 leiomyosarcomas.

53 There were no mutations in 3 leiomyomas and 4 leiomyosarcomas.

54 We investigated 94 leiomyomas and 60 corresponding myometrial tissues using

55 are at risk to develop cutaneous and uterine leiomyomas and an aggressive form of kidney cancer.

56 the minimal region deleted in 10% of uterine leiomyomas and in 10-20% of acute myeloid leukemias and

57 es thermocoagulation and necrosis in uterine leiomyomas and is feasible and safe, without serious con

58 cally and immunohistochemically from typical leiomyomas and leiomyosarcomas.

59 ive therapy in the management of symptomatic leiomyomas and may prove to be a valuable alternative to

60 transhiatal enucleation of lower oesophageal leiomyomas and other benign tumours with a combination o

61 te dehydrogenase have been linked to uterine leiomyomas and paragangliomas, and cancer cells have bee

62 ne mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutati

63 by the development of cutaneous and uterine leiomyomas and risk for development of an aggressive for

64 genetic abnormalities in leiomyosarcomas or leiomyomas and surveyed chromosomes 7, 9, 10, 11, 12, 14

65 tic locus for multiple cutaneous and uterine leiomyomas and the availability of an extended multigene

66 and gene-expression profiling of 38 uterine leiomyomas and the corresponding myometrium from 30 wome

67 ew, noninvasive treatment method for uterine leiomyomas and to present a comparison with other curren

68 Leiomyomas and tumor-derived cells isolated from a rat m

69 interreader reproducibility (16 sarcomas; 26 leiomyomas) and impact of reader experience (29 sarcomas

70 luded subendometrial cysts, nabothian cysts, leiomyoma, and adenomyosis.

71 esenchymal submucosal tumors such as lipoma, leiomyoma, and gastrointestinal stromal tumors.

72 They were examined for cancer, polyp, leiomyoma, and hyperplasia.

73 ia, polycystic ovary syndrome, dysmenorrhea, leiomyoma, and postpartum initiation.

74 be indicated for treatment of endometriosis, leiomyomas, and benign prostatic hyperplasia.

75 ntiation of malignant sarcomas from atypical leiomyomas, and it may assist inexperienced readers.

76 esenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas.

77 Found in as many as 80% of women, uterine leiomyomas are a frequent cause of abnormal uterine blee

78 As leiomyomas are a hyperproliferation of smooth muscle cel

79 Uterine leiomyomas are benign but affect the health of millions

80 Uterine leiomyomas are benign tumors that can cause pain, bleedi

81 Uterine leiomyomas are common benign smooth muscle tumors that i

82 Uterine leiomyomas are extremely common estrogen and progesteron

83 Multiple cutaneous and uterine leiomyomas are inherited as an autosomal dominant trait,

84 Uterine leiomyomas are reported to be the most common benign gyn

85 Uterine fibroids (leiomyomas) are a major women's health problem.

86 Uterine fibroids (leiomyomas) are the most common tumors of the female rep

87 Leiomyomas arise from smooth muscle cells of the uterine

88 hown to cause multiple cutaneous and uterine leiomyomas as well as hereditary leiomyomatosis and rena

89 evaluate the role of HIFU in the therapy of leiomyomas as well as to review the actual clinical acti

90 LMS in resected masses presumed to represent leiomyoma, as high as one in 770 women (0.13%).

91 The authors investigated the risk of uterine leiomyoma associated with exposure to 2,3,7,8,-tetrachlo

92 th a large indication range for all sizes of leiomyomas, associated with high efficacy, low operative

93 ther, our results show that the common human leiomyoma-associated MED12 variant can cause leiomyomas

94 on described as multiple well-differentiated leiomyomas at sites distant from the uterus.

95 Clinical research on HIFU therapy for leiomyomas began in the 1990s, and the majority of patie

96 diagnosis of pulmonary benign metastasizing leiomyoma being stated.

97 Benign tumors (mainly leiomyoma being the most frequent and others such as lip

98 case each of sperm granuloma, spermatic cord leiomyoma, benign inflammatory nodule, and fibroma.

99 Benign metastasizing leiomyoma (BML) is a rare condition described as multipl

100 previously reported MED12 lesions in uterine leiomyoma but not those of other tumors.

101 essed in matched specimens of myometrium and leiomyoma by real-time qPCR, Western blot, and immunohis

102 alignant uterine leiomyosarcomas from benign leiomyomas by morphological criteria is not always possi

103 erials from 16 leiomyosarcomas and 13 benign leiomyomas by polymerase chain reaction for 26 microsate

104 d ultrasound surgery in treatment of uterine leiomyomas by using two treatment protocols.

105 Cutaneous leiomyomas can be associated with severe paroxysmal pain

106 Simvastatin potently stimulated leiomyoma cell apoptosis in a manner mechanistically dep

107 ty of the antiestrogen tamoxifen to modulate leiomyoma cell growth.

108 ession, whereas knockdown of KLF11 increased leiomyoma cell proliferation and abolished the antiproli

109 These findings indicate that MEHHP promotes leiomyoma cell survival by activating the tryptophan-kyn

110 , or AHR abolished MEHHP-mediated effects on leiomyoma cell survival.

111 h muscle cell; however, it is not known what leiomyoma cell type is responsible for tumor growth.

112 le in determining whether TSC2-null Elt3 rat leiomyoma cells apoptose in response to UPR induction by

113 in pathway that enables mature myometrial or leiomyoma cells to send mitogenic signals to neighboring

114 ing that the levels of IGF-I produced by the leiomyoma cells were physiologically significant.

115 ll factor 4 in LMSP cells, but not in mature leiomyoma cells, blocked the estrogen/progesterone-depen

116 eptor (ER) signaling pathways were intact in leiomyoma cells, in addition to growth inhibition, stimu

117 IGF-I autocrine loop in tamoxifen-sensitive leiomyoma cells, supporting the hypothesis that the pres

118 rone stimulates the proliferation of uterine leiomyoma cells, the mechanism of progesterone action is

119 of PR signaling and proliferation in uterine leiomyoma cells.

120 ing that this growth factor is mitogenic for leiomyoma cells.

121 vastatin inhibits the proliferation of human leiomyoma cells.

122 oliferation specifically in cultured primary leiomyoma cells.

123 ne receptor levels than mature myometrial or leiomyoma cells.

124 olving LMSP and differentiated myometrial or leiomyoma cells.

125 d be seeded from a single lineage of uterine leiomyoma cells.

126 articipants 18 years or older with cutaneous leiomyomas characterized by pain at least once weekly an

127 eeks, a robust and fast-growing Cd-Resistant Leiomyoma (CR-LM) cell culture was established.

128 In vitro, incubation of primary leiomyoma cultures with adenosine or its hydrolysis-resi

129 In vitro experiments with a leiomyoma-derived cell line demonstrated that the pan-PP

130 o inhibit the proliferation of three of five leiomyoma-derived cell lines (ELT cell lines) in vitro,

131 A2 locus in either primary rat leiomyomas or leiomyoma-derived cell lines that expressed HMGA2.

132 All LMSP and leiomyoma-derived main population (LMMP) but none of the

133 cell-enriched population, designated as the leiomyoma-derived side population (LMSP), is responsible

134 ouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2

135 vascular structures and the pseudocapsule of leiomyomas despite diffuse myometrial distribution.

136 consistently indicate a correlation between leiomyoma development and exposure to endocrine-disrupti

137 pal DEHP metabolite, and the risk of uterine leiomyoma diagnosis (n = 712 patients).

138 Well-perfused leiomyomas did not show greater volume reduction than th

139 ncer regulation as an important mechanism of leiomyoma disease pathogenesis.

140 a previous or coincident history of uterine leiomyoma, especially when no evidence of other malignan

141 ysregulated mTOR signaling as a component of leiomyoma etiology across species and directly show the

142 ve trial performed in the context of uterine leiomyoma evaluation.

143 Eker leiomyomas exhibited a 50% incidence of loss of the wild

144 udy was to determine if benign human uterine leiomyoma (fibroid) cells could be malignantly transform

145 Uterine leiomyomas (fibroids or myomas), benign tumours of the h

146 Uterine leiomyomas (fibroids) are a major source of gynecologic

147 of reproductive age are affected by uterine leiomyomas (fibroids).

148 that this alteration alone promotes uterine leiomyoma formation and hyperplasia in both WT mice and

149 eratively and it is important to distinguish leiomyomas from other tumors for prevention from superer

150 Uterine myometria and spontaneous leiomyomas from the Eker rat, which carries a germ-line

151 tic locus for multiple cutaneous and uterine leiomyomas, from 14 cM to an interval of 4.55 or 7.19 cM

152 entrations of adenosine as key regulators of leiomyoma growth and potentially identify novel strategi

153 pact, the mechanisms responsible for driving leiomyoma growth remain poorly understood.

154 The ability of tamoxifen to decrease leiomyoma growth was found to correlate with expression

155 nts MEHHP exposure as a high-risk factor for leiomyoma growth, uncovers a mechanism by which exposure

156 (41/46) of women with cutaneous and uterine leiomyomas had a total hysterectomy, 44% at age < or =30

157 aratesticular tumours can be benign (lipoma, leiomyoma, haemangioma) or malignant (rhabdomyosarcoma,

158 e explored transcriptional differences among leiomyomas harboring different genetic drivers, includin

159 plex cytogenetic abnormalities; in contrast, leiomyomas have simple or no cytogenetic abnormalities.

160 Uterine fibroids (leiomyomas) have historically been viewed as important c

161 exon 2 variants are associated with uterine leiomyomas; however, the causality of MED12 variants, th

162 ne fibrosis, we developed a 3D human uterine leiomyoma (ht-UtLM) spheroid culture model.

163 nds (ME(90)) after injection of the dominant leiomyoma immediately after embolization was correlated

164 s c-kit (+) stromal tumor in 14 patients and leiomyoma in 2 patients.

165 ent a case of pulmonary benign metastasizing leiomyoma in a female patient admitted to our hospital w

166 n monosodium glutamate (MSG)-induced uterine leiomyoma in albino rats and proposed their mechanisms o

167 gical examination confirmed the diagnosis of leiomyoma in both lesions.

168 leiomyoma-associated MED12 variant can cause leiomyomas in mice via a gain of function that drives ge

169 ition characterized by formation of multiple leiomyomas in the abdominal and pelvic peritoneum.

170 trial polyps were seen in 46 (47%) patients; leiomyoma, in 11 (11%); cancer, in four (4%); hyperplasi

171 E correlates with clinical response, whereas leiomyomas initially high in SI on T2-weighted images in

172 Leiomyomas initially high in SI on T2-weighted images sh

173 Pulmonary benign metastasizing leiomyoma is a rare entity.

174 Uterine leiomyoma is an estrogen-responsive tumor, and the prese

175 SERM) for the potential treatment of uterine leiomyoma is described.

176 Leiomyoma is the most common benign oesophageal tumour.

177 Uterine leiomyoma is the most common benign tumor in reproductiv

178 Uterine leiomyoma is the most common tumor in women and causes s

179 Uterine leiomyoma is the most common tumor of the female genital

180 Each leiomyoma is thought to arise from a single mutated myom

181 Each leiomyoma is thought to be a benign monoclonal tumor ari

182 Medical management of painful cutaneous leiomyomas is generally unsatisfactory.

183 uided focused ultrasound surgery for uterine leiomyomas is reported.

184 Myomectomy, the excision of uterine leiomyoma, is now commonly performed via minimally invas

185 l Med12-KO mice resulted in earlier onset of leiomyoma lesions that were also greater in size.

186 thout exclusion of other mesenchymal tumors (leiomyoma, lipoma, gastrointestinal stromal tumor, leiom

187 ulated proliferation of mesenchymal cells in leiomyomas, lipomas, hamartomas,and other diseases has b

188 studies have identified subtypes of uterine leiomyoma (LM) with distinctive genetic alterations.

189 its receptor, PR, are essential for uterine leiomyoma (LM, a.k.a., fibroid) tumorigenesis, but the u

190 nt at 3 months were higher with a submucosal leiomyoma location (P =.04); however, this association w

191 A submucosal leiomyoma location was associated with a greater volume

192 Immediate reduction in leiomyoma ME(90) correlated with clinical response (Spea

193 Initial leiomyoma ME(90) was lower (P <.001), but it suppressed

194 Our leiomyoma model driven by the Kras(G12V/+) mutation will

195 vus (n = 1; 3%), hemorrhage (n = 1; 3%), and leiomyoma (n = 1; 3%).

196 ronic diarrhea (n = 4, 27%), and EBV-related leiomyoma (n = 2, 13%).

197 neralized lymphoproliferative disorder and a leiomyoma of the liver a year later.

198 gland (1), surgical wound inflammation (2), leiomyoma of the uterus (1), suture granuloma (1), and e

199 Uterine leiomyomas or fibroids (UFs) are benign tumors character

200 ved at the HMGA2 locus in either primary rat leiomyomas or leiomyoma-derived cell lines that expresse

201 ene mutations were found in gastrointestinal leiomyomas or leiomyosarcomas.

202 r nine non-ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29, p=1.17 x 10(-5)).

203 Uterine leiomyomas (or fibroids) are the most common tumors in w

204 As a basis for understanding leiomyoma pathogenesis and identifying targets for pharm

205 exposure to environmental phthalate impacts leiomyoma pathogenesis, and may lead to the development

206 or REST in epigenetic regulation relevant to leiomyoma pathophysiology.

207 Half of all leiomyoma patients have oesophagus-associated complaints

208 Immediate reduction in leiomyoma perfusion after bilateral UAE correlates with

209 myometrial perfusion returned to normal, but leiomyoma perfusion remained suppressed (P <.001).

210 These results suggest that in uterine leiomyomas PPARgamma activation is growth inhibitory and

211 Extrauterine leiomyomas present a greater diagnostic challenge becaus

212 Cutaneous leiomyomas, rare benign tumors originating from the arre

213 hormone (LH) levels, the MSG-induced uterine leiomyoma rats also had noticeably higher levels of test

214 Six leiomyomas received full therapeutic doses, and 98.5% of

215 200,000 procedures annually, the etiology of leiomyoma remains largely unknown.

216 rentiation of uterine sarcomas from atypical leiomyomas remains a clinical challenge and is needed to

217 he first reported case of duplex oesophageal leiomyomas removed laparoscopically.

218 cancer, Birt-Hogg-Dube syndrome, hereditary leiomyoma renal cell carcinoma, familial renal oncocytom

219 zes the need for molecular stratification in leiomyoma research and possibly in clinical practice as

220 r regulator of epigenetic gene silencing, in leiomyoma results in the upregulation of ESR1 targets an

221 issue samples from different tumor entities (leiomyoma, seminoma, mantle cell lymphoma, melanoma, bre

222 Microarray analyses of 80 LMSs and 24 leiomyomas showed a significant elevated expression of v

223 Leiomyoma side-population (LMSP) cells comprising 1% of

224 Smaller baseline leiomyoma size and submucosal location are more likely t

225 Using matched pairs of human myometrial and leiomyoma smooth muscle cells from the same uterus, we d

226 In addition, cultured myometrial as well as leiomyoma smooth muscle cells rapidly silence both estro

227 eceptor (PR) target genes in primary uterine leiomyoma smooth muscle cells.

228 Expression of HMGI(Y) protein in this leiomyoma specimen is increased dramatically as compared

229 This report describes a uterine leiomyoma specimen with an inv(6)(p21q15).

230 estradiol and progesterone on these uterine leiomyoma subtypes emphasize the importance of subtypes

231 cteristics of the two most prevalent uterine leiomyoma subtypes, MED12-mutant (MED12-LM) and HMGA2-ov

232 y was driven by progesterone in both uterine leiomyoma subtypes.

233 consistent with a role in the initiation of leiomyoma, such as translocations of the HMGA2 and RAD51

234 ecurrent and mutually exclusive mutations in leiomyomas, suggesting the involvement of molecularly di

235 aggressive cancer; its common occurrence in leiomyomas suggests that it also has a role in the genes

236 predispose to multiple cutaneous and uterine leiomyoma syndrome (MCL) and MCL associated with renal c

237 Uterine fibroids (leiomyomas), the most common tumors in women and those a

238 scription factor AP-1 is highly prevalent in leiomyomas, the functional consequence of AP-1 loss on g

239 e novel proteogenomic alterations in uterine leiomyoma tissues collected from HLRCC patients and unde

240 KLF11 expression was significantly lower in leiomyoma tissues compared with adjacent myometrial tiss

241 -C, and RNA-sequencing of matched normal and leiomyoma tissues, here we show that modified enhancer a

242 6, which remained constitutively elevated in leiomyoma tissues.

243 n deciphering the malignant progression from leiomyoma to leiomyosarcoma.

244 ne of 56 mesenchymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusivel

245 phenotypic association observed for uterine leiomyoma (UL) and breast cancer (BC).

246 In vitro studies have shown that uterine leiomyoma (UL) cells proliferate in response to IGF-I an

247 een in benign smooth muscle tumor as uterine leiomyoma (UL).

248 Uterine leiomyomas (UL) are benign tumors that arise in the myom

249 on well-differentiated benign lesions called leiomyomas (ULM), and rare, highly aggressive and pleomo

250 and increase the risk of developing uterine leiomyomas (ULMs).

251 A global comparison of mRNA from leiomyoma versus myometrium in human and rat identified

252 disease associations (hypertension, uterine leiomyoma, vitamin D deficiency, atopic eczema) and phen

253 eters were baseline uterine volume, baseline leiomyoma volume and location, and number of leiomyomas.

254 lk-related symptoms were not associated with leiomyoma volume change or location.

255 ession models indicated that larger dominant leiomyoma volume was associated with a smaller percentag

256 The association with uterine leiomyoma was borderline significant in Black women (OR,

257 f botulinum toxin to treat painful cutaneous leiomyomas was associated with improved quality of life

258 tumor-suppressor gene predisposed to uterine leiomyomas, we show that an early-life exposure to dieth

259 ause of chromosomal abnormalities in uterine leiomyomas; we propose that tumorigenesis occurs when ti

260 Approximately 90% of cells in HMGA2-uterine leiomyoma were smooth muscle cells (SMC) with HMGA2 over

261 Human leiomyomas were also found to express all three PPAR iso

262 hed specimens of healthy myometrium, uterine leiomyomas were characterized by reduced CD73 expression

263 informed consent, patients with symptomatic leiomyomas were consecutively enrolled and treated at on

264 Studies addressing HIFU in leiomyomas were identified from a search of the Internet

265 Forty-five leiomyomas were noted (mean, four per patient).

266 the 1990s, and the majority of patients with leiomyomas were treated predominantly with HIFUNIT 9000

267 FH-deficient leiomyomas were uniquely characterized by activation of

268 leven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exceptionally rare in c

269 case of a duplicated lower-third oesophageal leiomyoma, which was completely removed via the laparosc

270 sponsible for multiple cutaneous and uterine leiomyomas, which, in turn, may provide key information

271 y of solid tumors, including breast cancers, leiomyomas, Wilms' tumors, rhabdomyosarcomas, liposarcom

272 power morcellation, or fragmentation of the leiomyoma with a mechanical device, may be used to facil

273 he initial diagnosis of benign metastasizing leiomyoma with no evidence of neoplastic cells within th

274 Leiomyomas with a rare growth pattern occur most often i

275 Leiomyomas with HMGA2 aberrations displayed highly signi

276 esulting in expression signatures as seen in leiomyomas with HMGA2 aberrations.

277 tic locus for multiple cutaneous and uterine leiomyomas, with a maximum two-point LOD score of 4.453

278 HMGI(Y) expression was also found in 8 of 16 leiomyomas without cytogenetically detectable chromosome

279 ristics, are necessary for in vivo growth of leiomyoma xenograft tumors.